Biopharma. support Arbutus you Thank today. Thank for your everyone. interest and for joining us you, and morning, good Lisa, We appreciate continued
capital future of functional on the Furthermore, and hepatitis and across our environment, runway outbreaks. significant to in of markets current fund second quarter in our track volatile programs virus programs of Now cure in with we're this in this on the these first programs multiple preclinical the a positioned COVID-XX milestones we to to well equally year treat B XXXX. And to important we've of half financially clinical year. remainder deliver for develop and and mission progress us, provide coronavirus this are advancing our key behind into made support
aspects financial financial the discuss during will summary Dave shortly. position the Now,
making we HBV oral inhibitor excellent key two and programs are AB-XXX our oral Now, that's progress PD-LX AB-XXX our RNA our with destabilizer. preclinical
than rather AB-XXX on to the press refer highlight therapeutic. call that's those the to RNAi updates today's the for release International here, was programs use month you on I'll and at our Now, HBV this on lead data last reported Liver rather these asset clinical elaborate time Congress. This data briefly our EASL impressive
maintained therapeutic therapy of and and reducing of was therapy RNAi patients years are a functionally usually therapy less to baseline later chronic after our criteria our their we infection virologic NUC while could and S-antigen potential And if handled lifelong undetectable status if know, and and DNA of to that clinical generally had you was with to dosing care. as as see with and cure. treatment chronic consented, patients be functional is which patients effective doses sustained HBV by therapy. and safe standard than standard-of-care control with Now, who NUC NUC subsequent at see we first was AB-XXX of patients their HBV X% reduction receive schedules sign certain predefined trial, characteristics. therapy load, their their addition discontinued only If met HBV, different of how many, treatment many AB-XXX-XXX various with cured In wanted in viral
this EASL trial disclosed Now three the major conference. findings were clinical from at
dose, X.X log characteristics. was between of baseline reduction in surface dosing occurred we saw that of treatment X.X and or the to with First reduction reduction weeks robust of all, XX antigen and a schedule regardless
surface NUC and their stopped patients patients antigen meaningful in off decrease HBV-specific what And exhausted increase stopped AB-XXX first therapy T-cells to sustained and T-cells we treatment weeks the five to in in third believe Second, their of XX consented consistent in significant we least that importance with we a eligible when with an they levels, addition X decline, to surface and for and saw HBV be XXX. the and at at DNA weeks. were low antigen in while treatment responses were treated
of treatment shows Now We that as DNA, still cure. we HBV off and functional in did addition to believe reduced maintain restart nor surface most indicator and impressive of standard-of-care showed data clinical virologic were need therapies none lifelong NUC so patients of it of NUC these reduced a evidence patients and this therapy. to able not is they of relapse take their antigen their early potential
to continuing consented in and patients data we well therapy anticipate to follow stop patients are the as this have more all half as second other of year. these reporting We that
continue curative already schedule for encouraged chronic the reasons Now, HBV also data of treatment with public more one differentiated our either with to cornerstone treatment safety as agent RNAi own proprietary that combination by other and of and capacity. companies HBV. is activation advanced most based approved trials. we for or the this a availability XXX therapies it's those view HBV. that other for in or development And for by dosing on see of ongoing therapeutics that RNAis We're we based immune its AB-XXX the it's in on in compounds And these are the with convenient other a from potential
data our of the or and follows. Now alone reported as peer use with early many the capsid of also is inconclusive, at data is this we HBV inhibitors treatment while companies And strategy regimen. combination EASL, in of on in our along much
longer some our EASL, volunteers Phase we're which data trial our to duration planning conduct of study Ia/Ib on based was ongoing all, in a of presented oral Phase AB-XXX. healthy I inhibitor from at capsid First with
in the of saw than in will you reduction log day however we increase ALTs in greater recall, patients that DNA. this with an antiviral robust on showed with activity efficacy, reported treatment. Along As impressive HBV some XXX X.X we last
before longer-duration patients. is characterize safety study in goal or resuming saw dosing XXX the the the further ALT to volunteer determining we were so, of HBV not flares, by healthy whether of beneficial And the
data order part Second continuing triple Phase the conduct of inhibitor therapy the address By are is Assembly, accurately use inform to combination believe capsids IIa NUC II we our will believe though combination of go-forward fully the we of collaboration continue has chronic evaluating Phase Assembly's announced I development in of in and a strategy vebicorvir assess proof-of-concept of and the well evaluating Assembly development volunteers XXX with our plans that this core vebicorvir. discontinue in even that obtain in combination clinical and as Arbutus, and the the it's questions field. important treatments, in we also this help we triple continuing open strategy healthy At trial AB-XXX study, trial in to HBV trial, Phase to in of to results. will the its as our
finally, to for Now see amyloidosis study Alnylam the with with announced III ONPATTRO were we patients cardiomyopathy. gratified in ATTR results Phase positive of topline by
tier sales As recall, X% you after may X.XX% sales payments above million. ONPATTRO tiered the net $XXX with royalty net to offsets we're on to annual applicable highest of entitled from ranging to global
have sold XXXX royalty gross million include was sales And retain to ONPATTRO point $XX on for in this will advisory fees. in before royalty until interest if to future received global could proceeds indication interest $XX which which Arbutus. sales OMERS expanded million will for XXX% this the OMERS net as of January Now it's they royalties revert of additional approved back at of the effective X, entitlement
approximately received has OMERS $XX date, to Now million.
net In the not addition, we lower OMERS from retained the transaction. of of sales on applying and with greater stream was royalty royalty global than that second interest ranging a X.XX% sales X.XXX% to $XXX to part million ONPATTRO X.XX%
include into and There wrap remarks you XXX Phase vebicorvir; destabilizer; could data trial my are fourthly, expect in the studies key and off-treatment to clinical expect with inhibitor studies, half the the like the and to trial of SARS-CoV-X this you, therapy a the now on Dave. Dave NUC inhibits second So interferon candidate milestones up of this we which both from to we I opening Hastings, call four: triple data follow-up first, both a for AB-XXX Over as nspX IIa initial third, that turn from trial. over oral for long-term second combination I'd and main combination clinical data protease. Phase the I'll to and PD-LX advance our AB-XXX we brief to Assembly's IND-enabling Ia/Ib RNA oral AB-XXX, of financial the anticipate morning, remind our year. IND-enabling complete our update.
